Merck & Co., Inc. (MRK)
After hours:
| Previous close | 118.59 |
| Open | 119.10 |
| Bid | 117.85 x 1100 |
| Ask | 117.89 x 800 |
| Day's range | 117.66 - 120.30 |
| 52-week range | 99.14 - 134.63 |
| Volume | |
| Avg. volume | 9,593,922 |
| Market cap | 298.702B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 21.82 |
| EPS (TTM) | 5.40 |
| Earnings date | 31 Oct 2024 |
| Forward dividend & yield | 3.08 (2.61%) |
| Ex-dividend date | 16 Sept 2024 |
| 1y target est | 140.15 |
Business WireIfinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
BASKING RIDGE, N.J. & RAHWAY, N.J., September 07, 2024--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) continues to demonstrate promising objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). These data were featured today as part of a press conference and will be presented during an oral presentation (OA04.03) on Sunday at the 2024 World Conference on
Simply Wall St.Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Business WireMerck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
RAHWAY, N.J., September 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candidates in more than 20 types of cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from Sept. 13-17. Study findings from the Phase 3 KEYNOTE-522 trial (#LBA4) in high-risk early-stage triple-negative breast cancer (TNBC), the Phase 3 KEYNOTE-A18 trial (
